Journal article
Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Denzil Furtado, Mattias Bjornmalm, Scott Ayton, Ashley I Bush, Kristian Kempe, Frank Caruso
ADVANCED MATERIALS | WILEY-V C H VERLAG GMBH | Published : 2018
Abstract
Therapies directed toward the central nervous system remain difficult to translate into improved clinical outcomes. This is largely due to the blood-brain barrier (BBB), arguably the most tightly regulated interface in the human body, which routinely excludes most therapeutics. Advances in the engineering of nanomaterials and their application in biomedicine (i.e., nanomedicine) are enabling new strategies that have the potential to help improve our understanding and treatment of neurological diseases. Herein, the various mechanisms by which therapeutics can be delivered to the brain are examined and key challenges facing translation of this research from benchtop to bedside are highlighted...
View full abstractRelated Projects (2)
Grants
Awarded by Australian Research Council (ARC) under the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
Awarded by National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship
Awarded by NHMRC-ARC Dementia Research Development Fellowship
Awarded by NHMRC Fellowship
Awarded by NIH Research Project Grant
Awarded by H2020/European Union through a Marie Sklodowska-Curie Individual Fellowship
Funding Acknowledgements
This article is part of the Advanced Materials Hall of Fame article series, which recognizes the excellent contributions of leading researchers to the field of materials science. This research was supported by the Australian Research Council (ARC) under the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (Project No. CE140100036) and the Yulgilbar Foundation and Melbourne Neuroscience Institution. F.C. and K.K. gratefully acknowledge the award of a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (F.C., APP1135806) and an NHMRC-ARC Dementia Research Development Fellowship (K.K., APP1109945). A.I.B. is supported by an NHMRC Fellowship (GNT1103703), Project Grant (GNT1123625), and Program Grant (GNT11326040), and an NIH Research Project Grant (1RF1AG054057-01). M.B. acknowledges support from H2020/European Union through a Marie Sklodowska-Curie Individual Fellowship (grant agreement no. 745676). The authors thank Alison E. Burke and Cassio Lynm for assistance with preparing figures.